公开(公告)号：EP3744323A1

公开(公告)日：2020-12-02

申请号：EP19743131.5

申请日：2019-01-25

申请人： AJINOMOTO CO., INC.

发明人： SUGA, Yasuyo ,  SASAHARA, Ikuko ,  HASHIMOTO, Masaki ,  MINE, Tomoyuki ,  TAKADA, Michihiro ,  ISHII, Makoto ,  KANZAKI, Michiya

IPC分类号： A61K31/202 ,  A23L33/115 ,  A23L33/175 ,  A61K31/198 ,  A61P25/04 ,  A61P43/00

摘要： The present invention aims to provide a composition having a prophylactic or improvement effect on nociceptive pain.
The present invention relates to a composition for preventing or improving nociceptive pain, which contains an amino acid containing serine, and a lipid containing n-3 fatty acid.

公开(公告)号：EP2124059A1

公开(公告)日：2009-11-25

申请号：EP08703771.9

申请日：2008-01-24

申请人： Ajinomoto Co., Inc. ,  Keio University

发明人： MURAMATSU, Takahiko ,  ANDOU, Ayatoshi ,  HIBI, Toshifumi ,  HISAMATSU, Tadakazu ,  OKAMOTO, Susumu ,  SAKAI, Ryosei ,  ONO, Nobukazu ,  SUZUKI, Manabu ,  ANDO, Toshihiko ,  HASHIMOTO, Masaki

IPC分类号： G01N33/68 ,  A61B10/00

CPC分类号： G01N33/6806 ,  G01N33/6893 ,  G01N2800/065 ,  G06F19/24

摘要： Provided are a method of evaluating IBD, an amino acid data processor, an amino acid data-processing method, an amino acid data-processing system, an amino acid data-processing program and a recording medium, which are capable of evaluating an IBD state accurately by utilizing the concentration of amino acids in blood. According to the method of evaluating IBD of the present invention, amino acid concentration data on the concentration value of amino acid in blood collected from a subject to be evaluated is measured, and an inflammatory bowel disease state in the subject is evaluated based on the measured amino acid concentration data of the subject.

摘要翻译： 本发明提供了在氨基酸数据处理器评估IBD，氨基酸的数据处理方法中，在氨基酸的数据处理系统中，氨基酸的数据处理程序的一种方法和一种记录介质，其能够评估IBD状态的 利用通过准确的血液中氨基酸的浓度设定。 。根据本发明的评价IBD的方法中，氨基酸上的在从待评估的个体收集的血液氨基酸浓度值的酸浓度数据被测量，并且在受试者炎性肠疾病状态是基于所测量的评价 受试者的氨基酸浓度数据。

公开(公告)号：EP1920770A1

公开(公告)日：2008-05-14

申请号：EP06780740.4

申请日：2006-07-03

申请人： Ajinomoto Co., Inc.

发明人： MATSUMOTO, Hideki ,  OKUTSU, Tomohisa ,  TAKEDA, Tomoko ,  SUZUKI, Hideki ,  YANO, Tetsuo ,  HASHIMOTO, Masaki ,  ONO, Miho ,  SUZUKI, Manabu

IPC分类号： A61K31/198 ,  A61K31/405 ,  A61K31/4172 ,  A61P1/00 ,  A61P1/04 ,  A61P37/02 ,  A61P43/00

CPC分类号： A61K31/198 ,  A61K31/405 ,  A61K31/4172 ,  Y02A50/411 ,  A61K2300/00

摘要： Disclosed is an agent for use in the treatment or prevention of inflammatory bowel disease. Also disclosed is an agent for inhibiting the production of TNF-α. A therapeutic or prophylactic agent for inflammatory bowel disease comprising at least one amino acid selected from the group consisting of lysine, histidine, phenylalanine, methionine, tryptophan, glutamine, glycine, cysteine, cystine and threonine, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day; and a TNF-α production inhibitor comprising an amino acid selected from the group consisting of histidine, phenylalanine and tryptophan, the amino acid being administered at a dose of 0.1 to 4000 mg/kg per day.

摘要翻译： 公开了用于治疗或预防炎症性肠病的药剂。 还公开了抑制TNF-α产生的药剂。 包含至少一种选自赖氨酸，组氨酸，苯丙氨酸，甲硫氨酸，色氨酸，谷氨酰胺，甘氨酸，半胱氨酸，胱氨酸和苏氨酸的氨基酸的炎症性肠病治疗或预防剂，所述氨基酸以 每日0.1〜4000mg / kg; 和包含选自组氨酸，苯丙氨酸和色氨酸的氨基酸的TNF-α产生抑制剂，所述氨基酸以每天0.1至4000mg / kg的剂量施用。

公开(公告)号：EP3273245A1

公开(公告)日：2018-01-24

申请号：EP16764985.4

申请日：2016-03-15

申请人： Ajinomoto Co., Inc.

发明人： HISAMATSU, Tadakazu ,  KANAI, Takanori ,  HIBI, Toshifumi ,  ONO, Nobukazu ,  IMAIZUMI, Akira ,  HASHIMOTO, Masaki ,  MORI, Maiko ,  UO, Michihide

IPC分类号： G01N33/68 ,  G01N33/48

CPC分类号： G01N33/492 ,  G01N33/50 ,  G01N33/6812 ,  G01N33/6827 ,  G01N33/72 ,  G01N2800/065 ,  H04L1/0061

摘要： Provided is the evaluating method and the like, which can provide reliable information that may be helpful in knowing the future risk of relapse of ulcerative colitis. In the present embodiment, (i) the concentration data on the concentration value of histidine, albumin, hemoglobin, or glutamic acid in blood of the subject with ulcerative colitis in a remission phase is obtained and (ii) the future risk of relapse of ulcerative colitis for the subject is evaluated using the concentration value of histidine, albumin, hemoglobin, or glutamic acid included in the obtained concentration data of the subject.

摘要翻译： 提供的评估方法等可提供可能有助于了解溃疡性结肠炎复发风险的可靠信息。 在本实施方式中，（i）获得缓解期的溃疡性结肠炎患者的血液中组氨酸，白蛋白，血红蛋白或谷氨酸的浓度值的浓度数据，（ii）溃疡性复发的未来风险 使用所获得的受试者的浓度数据中包含的组氨酸，白蛋白，血红蛋白或谷氨酸的浓度值来评估受试者的结肠炎。